You may find more results for this query on our sister sites: GenomeWeb and 360Dx.
The first prospective study of BRAF-mutated cholangiocarcinoma showed a 51 percent response rate among patients treated with Novartis' Tafinlar and Mekinist.
In the upcoming clinical trial, the companies will evaluate the effects of IDEAYA's PKC inhibitor IDE196 and Pfizer's MEK inhibitor binimetinib.
The study will evaluate the effects of investigational drug IN10018 as a monotherapy and in combination with a MEK inhibitor.
A new study supports the development of BET inhibitors for MYCN-driven triple negative breast cancer as a single agent and in combination with a MEK inhibitor.
The Phase I trial, which will focus on studying BRAF-mutated solid tumors, has enrolled its first patient in Australia and will soon expand to sites in the US.
More individuals treated with BRAF- and MEK-targeted drugs were still alive after four years than would be expected with conventional chemo drugs.